Following the hypothesis that tau dysfunction in tauopathies results from a loss of normal tau function, an agent that stabilizes microtubules and prevents axonal/dendritic degeneration may restore function and ameliorate symptoms. Three agents have been developed following this hypothesis, but only one remains in active development.
